Table 2.
Subgroup analyses of interested FET outcomes in women with and without GnRHa pretreatment. (A) Subgroup analysis of study design. (B) Subgroup analysis of the type of GnRHa (C) Subgroup analysis of the duration of pituitary suppression with GnRHa.
| Outcomes | I2 | OR (95% CI) | p | p-Value for Subgroup Differences κ | |
|---|---|---|---|---|---|
| (A) Subgrouping: Study design | |||||
| CPR | RCTs (k = 14) | 18.00% | 1.09 (0.87–1.36) | 0.45 | 0.13 |
| Observational studies (k = 30) | 77.20% | 1.33 (1.13–1.55) | <0.001 * | ||
| IR | RCTs (k = 12) | 0.00% | 1.01 (0.85–1.20) | 0.88 | 0.04 * |
| Observational studies (k = 15) | 80.80% | 1.40 (1.13–1.73) | 0.004 | ||
| LBR | RCTs (k = 5) | 37.80% | 1.14 (0.68–1.41) | 0.63 | 0.44 |
| Observational studies (k = 22) | 81.30% | 1.34 (1.06–1.70) | 0.02 | ||
| MR | RCTs (k = 11) | 44.60% | 0.75 (0.31–1.82) | 0.49 | 0.70 |
| Observational studies (k = 25) | 56.70% | 0.89 (0.71–1.10) | 0.26 | ||
| (B) Subgrouping: Type of GnRHa protocol | |||||
| CPR | Depot GnRHa (k = 29) | 72.10% | 1.25 (1.08–1.44) | 0.004 * | 0.15 |
| Daily GnRHa (k = 14) | 0.00% | 1.11 (1.02–1.21) | 0.02 * | ||
| IR | Depot GnRHa (k = 17) | 78.90% | 1.28 (1.02–1.59) | 0.03 * | 0.51 |
| Daily GnRHa (k = 10) | 1.70% | 1.17 (0.96–1.42) | 0.08 | ||
| LBR | Depot GnRHa (k = 19) | 72.10% | 1.19 (1.04–1.37) | 0.02 * | 0.75 |
| Daily GnRHa (k = 7) | 26.80% | 1.14 (0.86–1.52) | 0.18 | ||
| MR | Depot GnRHa (k = 25) | 48.20% | 0.93 (0.75–1.15) | 0.48 | 0.16 |
| Daily GnRHa (k = 10) | 0.00% | 1.10 (0.95–1.28) | 0.16 | ||
| (C) Subgrouping: Duration of pituitary suppression with GnRHa | |||||
| CPR | Within one cycle (k = 37) | 61.30% | 1.17 (1.04–1.32) | 0.01 * | 0.003 * |
| More than one cycle (k = 6) | 66.40% | 2.00 (1.29–3.10) | 0.01 * | ||
| IR | Within one cycle (k = 24) | 56.70% | 1.16 (1.02–1.32) | 0.03 * | 0.002 * |
| More than one cycle (k = 3) | 64.40% | 2.07 (0.97–4.43) | 0.05 * | ||
| LBR | Within one cycle (k = 24) | 77.80% | 1.28 (1.03–1.60) | 0.03 * | 0.58 |
| More than one cycle (k = 2) | 37.90% | 1.42 (0.24–8.39) | 0.24 | ||
| MR | Within one cycle (k = 32) | 53.70% | 0.87 (0.69–1.09) | 0.21 | 0.54 |
| More than one cycle (k = 3) | 72.60% | 0.50 (0.01–24.11) | 0.52 | ||
κ: All subgroup analyses were conducted using a random-effects model, chosen in response to the significant heterogeneity observed within the overall study population. *: Statistically significant. CPR: Clinical Pregnancy Rate; GnRHa: Gonadotropin Releasing Hormone agonist; IR: Implantation Rate; LBR: Live Birth Rate; MR: Miscarriage Rate; RCT: Randomized Controlled Trial.